Lasa Supergenerics Limited (LASA.BO)
INR 17.88
(2.88%)
INR 17.88
(2.88%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -65.08 Million INR | 139.64% |
| 2022 | -246.85 Million INR | -133.81% |
| 2021 | 84.12 Million INR | -65.65% |
| 2020 | 472.65 Million INR | 46.74% |
| 2019 | 301.79 Million INR | 204.33% |
| 2018 | 113.52 Million INR | -75.42% |
| 2017 | 412.79 Million INR | -8.9% |
| 2016 | 457.32 Million INR | 0.0% |
| 2015 | - INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 17.97 Million INR | 114.14% |
| 2023 Q1 | 40.54 Million INR | -11.78% |
| 2023 FY | - INR | 139.64% |
| 2023 Q2 | 11.27 Million INR | -72.19% |
| 2023 Q3 | 10.52 Million INR | -6.62% |
| 2023 Q4 | -39.8 Million INR | -478.12% |
| 2022 Q3 | -16.04 Million INR | -377.1% |
| 2022 Q1 | -81.19 Million INR | -859.58% |
| 2022 FY | - INR | -133.81% |
| 2022 Q4 | 45.95 Million INR | 386.43% |
| 2022 Q2 | -3.36 Million INR | 95.86% |
| 2021 Q1 | 46.41 Million INR | -49.59% |
| 2021 FY | - INR | -65.65% |
| 2021 Q4 | -8.46 Million INR | 27.6% |
| 2021 Q3 | -11.68 Million INR | -108.88% |
| 2021 Q2 | 131.58 Million INR | 183.47% |
| 2020 Q2 | 132.59 Million INR | 9.04% |
| 2020 FY | - INR | 46.74% |
| 2020 Q4 | 92.07 Million INR | -27.8% |
| 2020 Q1 | 121.59 Million INR | 11.57% |
| 2020 Q3 | 127.54 Million INR | -3.81% |
| 2019 FY | - INR | 204.33% |
| 2019 Q3 | 84.08 Million INR | 11.38% |
| 2019 Q2 | 75.48 Million INR | 47.35% |
| 2019 Q1 | 51.23 Million INR | 59.99% |
| 2019 Q4 | 108.98 Million INR | 29.62% |
| 2018 Q4 | 32.02 Million INR | 1158.69% |
| 2018 Q3 | 2.54 Million INR | -94.33% |
| 2018 Q2 | 44.87 Million INR | -14.6% |
| 2018 Q1 | 52.54 Million INR | 7959.66% |
| 2018 FY | - INR | -75.42% |
| 2017 FY | - INR | -8.9% |
| 2017 Q2 | 143.88 Million INR | -13.35% |
| 2017 Q4 | 652 Thousand INR | -99.52% |
| 2017 Q3 | 136.83 Million INR | -4.9% |
| 2017 Q1 | 166.06 Million INR | 0.0% |
| 2016 Q1 | 109 Million INR | 0.0% |
| 2016 FY | - INR | 0.0% |
| 2015 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 100.677% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 100.105% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 100.948% |
| Granules India Limited | 8.6 Billion INR | 100.756% |
| Indoco Remedies Limited | 2.64 Billion INR | 102.459% |
| Achyut Healthcare Limited | 524 Thousand INR | 12519.847% |
| Ajanta Pharma Limited | 12.56 Billion INR | 100.518% |
| Alkem Laboratories Limited | 24.19 Billion INR | 100.269% |
| Alpa Laboratories Limited | 86.12 Million INR | 175.563% |
| Brooks Laboratories Limited | 41.72 Million INR | 255.962% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 102.761% |
| Bajaj HealthCare Limited | 444.51 Million INR | 114.641% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 104.4% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 100.074% |
| Eris Lifesciences Limited | 6.98 Billion INR | 100.932% |
| FDC Limited | 4.4 Billion INR | 101.479% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 100.574% |
| Gufic Biosciences Limited | 1.48 Billion INR | 104.396% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 100.948% |
| Ipca Laboratories Limited | 13.29 Billion INR | 100.489% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | 120.12% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 21.332% |
| Laurus Labs Limited | 8 Billion INR | 100.813% |
| Lupin Limited | 36.96 Billion INR | 100.176% |
| Mankind Pharma Limited | 28.09 Billion INR | 100.232% |
| Medicamen Biotech Limited | 245.66 Million INR | 126.492% |
| Medico Remedies Limited | 150.37 Million INR | 143.278% |
| Megasoft Limited | 284.73 Million INR | 122.857% |
| NATCO Pharma Limited | 18.79 Billion INR | 100.346% |
| Piramal Pharma Limited | 13.05 Billion INR | 100.498% |
| RPG Life Sciences Limited | 1.28 Billion INR | 105.078% |
| Sigachi Industries Limited | 883.39 Million INR | 107.367% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 100.047% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 101.391% |
| Syncom Formulations (India) Limited | 430.27 Million INR | 115.125% |
| Unichem Laboratories Limited | 742.35 Million INR | 108.767% |
| Wanbury Limited | 985.49 Million INR | 106.604% |
| Windlas Biotech Limited | 781.72 Million INR | 108.325% |
| ZIM Laboratories Limited | 462.09 Million INR | 114.084% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 100.116% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 98.256% |
| Divi's Laboratories Limited | 25.43 Billion INR | 100.256% |
| Hester Biosciences Limited | 539.47 Million INR | 112.064% |
| Procter & Gamble Health Limited | 3.01 Billion INR | 102.159% |
| Amrutanjan Health Care Limited | 682.53 Million INR | 109.535% |
| Bal Pharma Limited | 345.59 Million INR | 118.831% |
| Strides Pharma Science Limited | 3.76 Billion INR | 101.729% |
| Venus Remedies Limited | 711.8 Million INR | 109.143% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 101.665% |
| Nectar Lifesciences Limited | 1.56 Billion INR | 104.162% |
| Shilpa Medicare Limited | 2.58 Billion INR | 102.515% |
| Aarti Drugs Limited | 3.24 Billion INR | 102.003% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 102.497% |
| Suven Life Sciences Limited | -992.78 Million INR | 93.445% |
| Ind-Swift Limited | 1.06 Billion INR | 106.11% |
| Valiant Laboratories Limited | 12.73 Million INR | 610.872% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 100.697% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 97.694% |
| Themis Medicare Limited | 562.6 Million INR | 111.568% |
| Hikal Limited | 2.69 Billion INR | 102.417% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 100.186% |
| Sequent Scientific Limited | 549.8 Million INR | 111.837% |
| Novartis India Limited | 1.26 Billion INR | 105.127% |
| Wockhardt Limited | 1.08 Billion INR | 106.026% |
| Jubilant Pharmova Limited | 8 Billion INR | 100.813% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | 598.239% |
| Neuland Laboratories Limited | 4.74 Billion INR | 101.371% |
| Morepen Laboratories Limited | 1.72 Billion INR | 103.771% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | 122.642% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | 137.2% |